Crizotinib
- Generic Name
- Crizotinib
- Brand Names
- Xalkori
- Drug Type
- Small Molecule
- Chemical Formula
- C21H22Cl2FN5O
- CAS Number
- 877399-52-5
- Unique Ingredient Identifier
- 53AH36668S
- Background
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusio...
- Indication
Crizotinib is a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test. Crizotinib is also indicated for the treatment of relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Refractory Anaplastic Large Cell Lymphoma, Recurrent Inflammatory Myofibroblastic Tumors, Refractory Inflammatory Myofibroblastic Tumors, Relapsed Anaplastic Large Cell Lymphoma, Unresectable Inflammatory Myofibroblastic Tumors
- Associated Therapies
- -
Lorlatinib Combinations in Lung Cancer
- First Posted Date
- 2020-03-02
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 96
- Registration Number
- NCT04292119
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
- Conditions
- Interventions
- First Posted Date
- 2020-02-25
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 19
- Registration Number
- NCT04283669
- Locations
- 🇺🇸
Children's National Medical Center (Site 775), Washington DC, District of Columbia, United States
🇺🇸Children's HealthCare of Atlanta (Site 950), Atlanta, Georgia, United States
🇺🇸Lurie Childrens Hospital of Chicago (Site 350), Chicago, Illinois, United States
Study of Crizotinib for ROS1 and MET Activated Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-09-10
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 50
- Registration Number
- NCT04084717
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2019-10-30
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 260
- Registration Number
- NCT04009317
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
Study of IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
- Conditions
- Interventions
- First Posted Date
- 2019-05-13
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- IDEAYA Biosciences
- Target Recruit Count
- 341
- Registration Number
- NCT03947385
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸San Francisco Oncology Associates, San Francisco, California, United States
🇺🇸Columbia University Medical Center - Herbert Irving Pavilion, New York, New York, United States
Study of Crizotinib in Children and Adolescents With Myofibroblastic Tumors
- First Posted Date
- 2019-03-14
- Last Posted Date
- 2019-03-14
- Target Recruit Count
- 25
- Registration Number
- NCT03874273
- Locations
- 🇷🇺
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-11-13
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 10
- Registration Number
- NCT03737994
- Locations
- 🇺🇸
Miller-Dwan Hospital, Duluth, Minnesota, United States
🇺🇸Fairview Southdale Hospital, Edina, Minnesota, United States
🇺🇸Grady Memorial Hospital, Delaware, Ohio, United States
Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL
- Conditions
- Interventions
- First Posted Date
- 2018-10-16
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- Mingzhi Zhang
- Target Recruit Count
- 20
- Registration Number
- NCT03707847
- Locations
- 🇨🇳
Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Long Term Safety Observation of Crizotinib in Chinese NSCLC Population
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 41
- Registration Number
- NCT03672643
- Locations
- 🇨🇳
Eastern Theater General Hospital ,QinHuai District Medical Area, Nanjing, Jiangsu, China
🇨🇳Jilin Province Cancer Hospital, Changchun, Jilin, China
🇨🇳Sichuan Province Cancer Hospital, Chengdu, Sichuan, China
Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer
- First Posted Date
- 2018-08-27
- Last Posted Date
- 2023-12-27
- Lead Sponsor
- Hunan Province Tumor Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT03647111
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.